Autologous MUC1-Specific Th1 Effector Cell Immunotherapy Induce Differential Levels of Systemic TReg Cell Subpopulations That Result in Increased Ovarian Cancer Patient Survival

Adoptive T cell immunotherapy using autologous lymphocytes is a viable treatment for patients with cancer and requires participation of Ag-specific CD4 and CD8 T cells. Here, we assessed the immunotherapeutic effects of autologous MUC1 peptide-stimulated CD4(+) effector cells following adoptive tran...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Dobrzanski, Mark J., Rewers-Felkins, Kathleen A., Quinlin, Imelda S., Samad, Khaliquzzaman A., Phillips, Catherine A., Robinson, William, Dobrzanski, David J., Wright, Stephen E.
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2805085/
https://ncbi.nlm.nih.gov/pubmed/19762283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2009.08.007
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares